Technology evaluation: FluINsure, ID Biomedical

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 212-220

  Munoz, Flor M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CHEMISTRY; EVALUATION; HUMAN; INFLUENZA; INTRANASAL DRUG ADMINISTRATION; MORTALITY; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, INTRANASAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PATENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 7944232054     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 276042 Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJ, Palache AM, Wilschut J VACCINE 1995 13 2 155-162
2. 386257 Intellivax, a company within Biocapital's portfolio, begins nasal flu vaccine phase I clinical trial. Intellivax International Inc PRESS RELEASE 2000 October 19
3. 406981 ID Biomedical announces positive results from human testing of intranasal flu vaccine: Subunit flu vaccine safe, well tolerated and elicits both mucosal and systemic immune responses. ID Biomedical Corp PRESS RELEASE 2001 April 24
4. 409941 ID Biomedical initiates expanded human testing of nasal influenza (flu) vaccine. ID Biomedical Corp PRESS RELEASE 2001 May 22
5. 429214 ID Biomedical files IND for nasal flu vaccine trial. ID Biomedical Corp PRESS RELEASE 2001 November 13
6. 434379 ID Biomedical begins trivalent nasal flu vaccine study. ID Biomedical Corp PRESS RELEASE 2001 December 20
7. 434696 Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH INFECT IMMUN 2001 69 7 4545-4553
8. 445344 ID Biomedical announces positive results from FluINsure clinical trial. ID Biomedical Corp PRESS RELEASE 2002 April 02
9. 453572 ID Biomedical proceeds to phase II clinical trial of FluINsure. ID Biomedical Corp PRESS RELEASE 2002 June 05
10. 456275 ID Biomedical announces phase II enrollment of FluINsure and StreptAvax. ID Biomedical Corp PRESS RELEASE 2002 June 25
11. 457334 ID Biomedical announces strong nasal immune responses in FluINsure clinical trial. ID Biomedical Corp PRESS RELEASE 2002 July 08
12. 463198 ID Biomedical announces complete enrollment of phase II trial for FluINsure. ID Biomedical Corp PRESS RELEASE 2002 September 05
13. 464438 Phase I safety and immunogenicity of FluINsure, proteosome-trivalent influenza vaccine, given nasally to adults. Halperin S, McNeil S, Smith B, Langley J, Allard F, Jones T, Burt D, White G, Mallett C, Lowell G, Fries L ICAAC 2002 42 Abs G-1219
14. 466868 ID Biomedical announces approval for the FluINsure vaccine challenge study in the United Kingdom. ID Biomedical Corp PRESS RELEASE 2002 October 15
15. 472658 ID Biomedical announces positive results from phase II test of FluINsure vaccine. ID Biomedical Corp PRESS RELEASE 2002 December 03
16. 478576 ID Biomedical announces positive results from FluINsure challenge study. ID Biomedical Corp PRESS RELEASE 2003 February 12
17. 488157 ID Biomedical announces further positive results from FluINsure challenge study. ID Biomedical Corp PRESS RELEASE 2003 May 01
18. 493744 ID Biomedical announces strong immunogenicity data from phase II trials of FluINsure. ID Biomedical Corp PRESS RELEASE 2003 June 16
19. 505429 ID Biomedical reports positive results from human challenge study of FluINsure vaccine. ID Biomedical Corp PRESS RELEASE 2003 September 18
20. 509272 ID Biomedical receives approval to begin field trial of FluINsure. ID Biomedical Corp PRESS RELEASE 2003 October 16
21. 512150 Phase I evaluation of an intranasal proteosome-influenza vaccine in healthy adults. Treanor J, Burt D, Lowell G, Fries L ANNU CONF VACCINE RES 2001 4 S32
22. 512172 Nasal immunization with subunit proteosome influenza vaccines induce serum HAI, mucosal IgA and protection against influenza challenge. Plante M, Jones T, Allard F, Torossian K, Guthier J, St Felix N, White GL, Lowell GH, Burt DS VACCINE 2001 20 1-2 218-225
23. 512174 A nasal proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS VACCINE 2003 21 (25-26) 3706-3712
24. 512248 Safety & immunogenicity of one- and two-dose regimens of proteosome-monovalent influenza vaccine given intranasally to normal adults. Fries L, Treanor J, Burt D, White G, Lowell GH ABS INT SYMPOSIUM RESP VIRAL INFECTIONS 2001 4
25. 512298 Phase I safety and immunogenicity of FluINsure, a proteosome-trivalent influenza vaccine given nasally to adults. Halperin SA, McNeil S, Smith B, Langley J, Allard F, Jones T, Burt D, White G, Mallett C, Lowell G, Fries L COMPANY PRESENTATION 2002
26. 512301 Novel intranasal vaccines: A case study of a nasal influenza vaccine using proteosome technology. White G IBC CONF FORMULATION STRATEGIES BIOPHARMACEUTICALS, San Diego, CA, USA 2001
27. 512304 Characterization of a novel nasal subunit influenza vaccine based on proteosome-HA complexes. Johnson E, Williams J, Torossian K, Gauthier J, Allard F, White G, Lowell G, Burt D OPTIONS INFLUENZA CONTROL Crete, Greece 2000 4
28. 512373 Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B, Klein M, Bengtsson KL, Morein B, Burt D J INFECT DIS 1998 177 5 1266-1274
29. 512381 Nasal Immunization with subunit proteosome influenza vaccines induce enhanced respiratory IgA and serum hemagglutination inhibition activity. Plante M, Jones D, Allard F, Torrossian K, Gauthier J, White G, Lowell G, Burt D ABS AM SOC MICROBIOL 2000 100 297
30. 516220 ID Biomedical reports positive laboratory confirmed influenza results from FluINsure vaccine. ID Biomedical Corp PRESS RELEASE 2003 December 05
31. 519198 ID Biomedical announces United States patent grant for non-live FluINsure vaccine. ID Biomedical PRESS RELEASE 2004 January 14
32. 520673 FluINsure proteasome nasal sub-unit flu vaccine. ID Biomedical Corp COMPANY WORLD WIDE WEB SITE 2003 November 07
33. 520913 Proteosome-lipopeptide vaccines: Enhancement of immunogenicity for malaria CS peptides. Lowell GH, Ballou WR, Smith LF, Wirtz RA, Zollinger WD, Hockmeyer WT SCIENCE 1988 240 485 3 800-802
34. 520918 Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax. Lowell GH, Ballou WR, Smith LF, Zollinger WD, Hochmeyer WT TRANS R SOC TROP MED HYG 1989 83 Suppl 101-102
35. 520932 Proteosome delivery of a protective 9B-antigen against Schistosoma mansoni. Tarrab-Hazdai R, Schechtman D, Lowell G, Pirak E, Arnon R INT J IMMNUNOPHARMACOL 1999 21 3 205-218
36. 520934 The complex of flavivirus envelope polypeptide with meningococcal proteosomes elicits formation of virus-neutralizing antibodies. Slavik I, Kuzemenska P, Kozuch O, Matoska J, Pokorny J, Sekeyova M ACTA VIROL 1991 35 4 313-321
37. 520984 Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Orr N, Robin G, Cohen D, Arnon R, Lowell GH INFECT IMMUN 1993 61 6 2390-2395
38. 521011 Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines. Orr N, Arnon R, Rubin G, Cohen D, Bercovier H, Lowell GH INFECT IMMUN 1994 62 11 5198-5200
39. 521012 Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, Cohen D, Lowell GH INFECT IMMUN 1995 63 6 2382-2386
40. 521014 Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: Immunogenicity and efficacy against lethal SEB intoxication in mice. Lowell GH, Kaminski RW, Grate S, Hunt RE, Charney C, Zimmer S, Colleton C INFECT IMMUN 1996 64 5 1706-1713
41. 521015 Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Lowell GH, Colleton C, Frost D, Kaminski RW, Hughes M, Hatch J, Hooper C, Estep J, Pitt L, Topper M, Hunt RE et al INFECT IMMUN 1996 64 11 4686-4693
42. 521017 Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, Arnon R VACCINE 1995 13 14 1353-1359
43. 526929 Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA MORB MORTAL WKLY REP 2003 52 RR08 1-36
44. 527041 Estimating deaths due to influenza and respiratory syncytial virus. Glezen WP, Couch RB J AM MED ASSOC 2003 289 19 2500
45. 527044 The burden of influenza illness in children with asthma and other chronic medical conditions. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR J PEDIATR 2000 137 6 856-864
46. 527045 The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin M N ENGL J MED 2000 342 4 225-231
47. 527046 Influenza control - unfinished business. Glezen WP J AM MED ASSOC 1999 281 10 944-945
48. 527047 Influenza vaccine: Ensuring timely and adequate supplies. O'Mara D, Fukuda K, Singleton JA INFECT MED 2003 20 11 548-554